by Mark L. Ratner
About a year and a half ago, Michael Nohaile, PhD, moved out of his role as Head of Corporate Strategy...
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs.